Video
Major considerations and updates in immunotherapy for advanced prostate cancer
Author(s):
“People's concepts of immunotherapy are unfortunately quite distorted. It is not just about checkpoint inhibitors,” says Susan F. Slovin, MD, PhD.
Video Player is loading.
In this video, Susan F. Slovin, MD, PhD, discusses takeaways of her presentation on immunotherapy in advanced prostate cancer, which was given at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, and upcoming research. Slovin is a medical oncologist at the Memorial Sloan Kettering Cancer Center in New York City, New York.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
Post-RP incontinence: Low procedure rates examined
Data link incontinence severity to post-radical prostatectomy care
Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
Expert discusses differentiating prostate cancer from age-related issues
Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
Ruben Olivares, MD, discusses remote robot–assisted HIFU for prostate cancer
Related Content
